Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $128.00

Key Points

• Truist Financial raised Dianthus Therapeutics’ price target to $128 from $110 and maintained a “buy” rating, implying 18.89% upside from the prior close.
• Analyst sentiment is broadly positive: Dianthus has a consensus “Moderate Buy” rating and an average price target of $124.27, with recent target increases from Wedbush and HC Wainwright.
• Dianthus reported a quarterly loss of $0.90 per share, missing estimates, while insiders sold $7.99 million of stock over the last quarter; shares recently traded at $107.66.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its target price upped by research analysts at Truist Financial from $110.00 to $128.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's price target indicates a potential upside of 18.89% from the company's previous close.

A number of other research analysts have also recently commented on DNTH. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush boosted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a research note on Wednesday. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. HC Wainwright increased their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a report on Thursday. Finally, Wall Street Zen raised shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $124.27.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH traded down $4.84 on Thursday, reaching $107.66. 240,958 shares of the company's stock traded hands, compared to its average volume of 973,844. Dianthus Therapeutics has a fifty-two week low of $18.08 and a fifty-two week high of $114.55. The firm has a market cap of $5.89 billion, a price-to-earnings ratio of -26.01 and a beta of 1.22. The stock has a 50 day moving average price of $94.02 and a 200-day moving average price of $79.98.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 25.73%. The business had revenue of $0.76 million during the quarter, compared to analysts' expectations of $0.30 million. As a group, equities research analysts anticipate that Dianthus Therapeutics will post -3.82 EPS for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of the business's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president owned 30,000 shares of the company's stock, valued at $2,424,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,779 shares of company stock valued at $7,985,235 over the last quarter. Insiders own 3.02% of the company's stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $27,000. First Horizon Corp purchased a new position in Dianthus Therapeutics in the 1st quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter valued at about $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $64,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after acquiring an additional 3,317 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source